Nyiro Gyula Orszagos Pszichiatriai Es Addiktologiai Intezet
- Address
- lock Available on a paid plan
Nervous System Diseases
The institute is conducting research focused on Parkinson's disease, migraine, and various epilepsy syndromes to test new treatments and improve long‑term safety profiles. Studies also target primary progressive multiple sclerosis with the aim of evaluating higher‑dose antibody therapy for slowing disability.
- Long‑term safety of novel oral agents in Parkinson’s disease
- Acute treatment efficacy for migraine attacks
- Adjunctive therapy for refractory focal‑onset epilepsy
- Disease‑modifying strategies in primary progressive multiple sclerosis
- Safety of investigational drugs in Dravet and Lennox‑Gastaut syndromes
Nyiro Gyula Orszagos Pszichiatriai Es Addiktologiai Intezet supports these investigations through its dedicated neurology unit.
Mental Disorders
Clinical work at the site includes trials for Major Depressive Disorder that explore novel adjunctive agents to reduce depressive symptoms. Research also addresses bipolar‑I mania by comparing new oral compounds with placebo to achieve faster mood stabilization.
- Evaluation of new antidepressant candidates in adult MDD
- Assessment of safety and tolerability of long‑term therapy for bipolar mania
- Comparison of rapid‑acting anxiolytics for seizure‑related agitation
- Investigation of novel mechanisms for mood episode control in bipolar disorder
- Open‑label extensions to monitor chronic use outcomes in psychiatric conditions
The Gyula Nyírő National Institute of Psychiatry and Addiction provides a multidisciplinary environment for advancing mental health research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 22 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nyiro Gyula Orszagos Pszichiatriai Es Addiktologiai Intezet
lock Showing 1 of 17 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 22 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE | 2 | Unknown | 2025-08-28 | 2025-10-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.